XML 63 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1
Research and License Agreements - Additional Information (Detail)
1 Months Ended 12 Months Ended
Jun. 30, 2015
USD ($)
May 31, 2014
USD ($)
Dec. 31, 2018
USD ($)
item
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Research and License Agreements          
Revenue $ 20,000,000 $ 15,000,000     $ 18,500
License Agreement | Pfizer          
Research and License Agreements          
Up-front payment received     $ 22,500,000    
Transaction price     22,500,000    
Non-cash consideration received     $ 0    
Research Services Agreement | University Of Basel          
Research and License Agreements          
Royalty payment due against license fees received (as a percent)     10.00%    
Consideration paid     $ 0 $ 0 $ 0
Achievement Of Specified Development Milestone | License Agreement | Pfizer | Maximum          
Research and License Agreements          
Potential milestone payments     115,000,000    
Achievement Of Specified Regulatory Milestone | License Agreement | Pfizer | Maximum          
Research and License Agreements          
Potential milestone payments     70,000,000    
Achievement Of Specified Levels Of Annual Net Sales Of Licensed Products | License Agreement | Pfizer | Maximum          
Research and License Agreements          
Potential milestone payments     $ 135,000,000    
Achievement Of First Commercial Sale Of Licensed Product | License Agreement | Pfizer          
Research and License Agreements          
Number of indications | item     2    
Achievement Of Dosing First Patient In Clinical Trial | License Agreement | Pfizer          
Research and License Agreements          
Non-refundable milestone payment received $ 20,000,000 $ 15,000,000      
Achievement Of Dosing First Patient In Clinical Trial | License Agreement | Pfizer | Maximum          
Research and License Agreements          
Number of indications | item     2